Department of Anesthesiology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Surgery. 2013 Apr;153(4):555-64. doi: 10.1016/j.surg.2012.09.017. Epub 2012 Dec 4.
We demonstrated previously that ischemic postconditioning (IPo) attenuated intestinal injury induced by intestinal ischemia/reperfusion (I/R), and thereafter employed a proteomic method to identify aldose reductase (AR), a differentially expressed protein in intestinal mucosal tissue, which was downregulated by intestinal I/R and upregulated by IPo. This study aimed to further explore the possible role of AR in intestinal protection conferred by IPo.
Intestinal ischemia was induced by clamping the superior mesenteric artery (SMA) for 60 minutes in male adult rats. Then rats were allocated into 7 groups based on the random number table. The control group involved only sham operation; the control + AR inhibitor epalrestat group underwent sham operation and epalrestat administration; the I/R with and/or without epalrestat groups had SMA clamped for 60 minutes followed by 120 minutes of reperfusion with and/or without epalrestat given before index ischemia; the IPo group underwent 3 cycles of 30 seconds of reperfusion and 30 seconds of re-occlusion imposed immediately on reperfusion; and the epalrestat or vehicle control dimethylsulfoxide + IPo groups had the drugs administrated 10 minutes before ischemia.
IPo resulted in significant intestinal protection evidenced as marked decreases in Chiu's score, reflecting changes intestinal histology, serum diamine oxidase activity, and intestinal mucosal levels of lactic acid, malondialdehyde, and myeloperoxidase, the apoptosis index, and downregulated cleaved caspase-3 protein expression; these changes were accompanied by an increase in superoxide dismutase activity and upregulation of AR protein levels. Epalrestat failed to protect against intestinal I/R insult, but abolished the protective effects of IPo.
These findings suggest that IPo attenuates intestinal I/R-induced intestinal injury via AR-mediated oxidative defense and apoptosis suppression; AR inhibition reverses the protective effects of IPo. AR seems to be an innate protective factor in this model of intestinal I/R.
我们之前的研究表明,缺血后处理(IPo)可减轻肠缺血/再灌注(I/R)引起的肠损伤,随后采用蛋白质组学方法鉴定了醛糖还原酶(AR),这是一种在肠黏膜组织中差异表达的蛋白质,其表达水平在肠 I/R 后下调,在 IPo 后上调。本研究旨在进一步探讨 AR 在 IPo 介导的肠保护中的可能作用。
通过夹闭肠系膜上动脉(SMA)60 分钟诱导肠缺血。然后,根据随机数字表将大鼠分为 7 组。对照组仅行假手术;对照组+AR 抑制剂依帕司他组行假手术并给予依帕司他;I/R 组夹闭 SMA60 分钟,再灌注 120 分钟,再灌注前给予或不给予依帕司他;IPo 组再灌注即刻给予 3 个 30 秒再灌注/30 秒再闭塞循环;依帕司他或载体对照二甲基亚砜+IPo 组在缺血前 10 分钟给予药物。
IPo 显著减轻肠损伤,表现为 Chiu 评分显著降低,反映肠组织学变化、血清二胺氧化酶活性以及肠黏膜乳酸、丙二醛和髓过氧化物酶水平、细胞凋亡指数和下调的 cleaved caspase-3 蛋白表达降低;这些变化伴随着超氧化物歧化酶活性增加和 AR 蛋白水平上调。依帕司他不能保护肠 I/R 损伤,但可消除 IPo 的保护作用。
这些发现表明,IPo 通过 AR 介导的氧化防御和凋亡抑制减轻肠 I/R 引起的肠损伤;AR 抑制逆转了 IPo 的保护作用。在这种肠 I/R 模型中,AR 似乎是一种固有保护因子。